Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"$5.0 million","newsHeadline":"Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals for Olaratumab

    Menu

    Olaratumab

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

              Details:

              LY3012207 (olaratumab) is a mAb targeting PDGFRα. It was granted accelerated approval in the U.S. and conditional approval in the EU based on Phase II trial data which showed a 1-year survival benefit in patients with STS, when given in combination with standard chemotherapy.

              Lead Product(s): Olaratumab,Doxorubicin Hydrochloride

              Therapeutic Area: Oncology Product Name: LY3012207

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Telix Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab

              Details:

              The exclusive worldwide licence will allow Telix to repurpose LY3012207 (olaratumab) as a targeting agent for radiopharmaceutical imaging and therapy of cancer.

              Lead Product(s): Olaratumab,Doxorubicin Hydrochloride

              Therapeutic Area: Oncology Product Name: LY3012207

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $230.0 million Upfront Cash: $5.0 million

              Deal Type: Licensing Agreement April 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY